Arbutus Biopharma Corp Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Arbutus Biopharma Corp (ABUS) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $11.75 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-23
CAD
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|
| 2012-12-31 | -2.50M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | -1.65M CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | 2.88M CAD 20-F · filed 2013-03-27 |
USD
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $11.75M 10-K · filed 2026-03-23 | |
| 2023-12-31 | $18.43M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $14.56M 10-K · filed 2024-03-05 | |
| 2021-12-31 | $15.93M 10-K · filed 2023-03-02 | |
| 2020-12-31 | $12.03M 10-K · filed 2022-03-03 | |
| 2019-12-31 | $19.08M 10-K · filed 2021-03-04 | |
| 2018-12-31 | $13.06M 10-K · filed 2020-03-05 | |
| 2017-12-31 | $6.95M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $17.04M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $3.67M 10-K · filed 2018-03-16 | $3.68M 10-K · filed 2016-03-09 |
| 2014-12-31 | $6.60M 10-K · filed 2017-03-22 | $5.55K 10-K · filed 2015-03-13 |
| 2013-12-31 | $2.41M 10-K · filed 2016-03-09 | $565.15K 6-K · filed 2014-03-06 |
| 2012-12-31 | $798.00 10-K · filed 2015-03-13 | -$2.52M 6-K · filed 2014-03-06 |
| 2011-12-31 | -$1.62M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |